Clinical trials: Hepatic Neoplasms
Hepatitis B, Chronic
Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis
Chronic Hepatitis B infection (CHB) is known as the most frequently identified cause of liver disease that predisposes patients to the development of hepatocellular carcinoma (HCC).
- Trial name
- NCT02224456
- Testing
- Tenofovir disoproxil fumarate
- Where
- 19 sites in China
- Volunteers
- 197 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Hepatocellular
A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer
The primary purpose of the study is to explore whether treatment with PF-03446962 and best supportive care is better than placebo plus best supportive care in prolonging survival of patients affected by recurrent liver cancer.
- Trial name
- NCT01911273
- Testing
- PF-03446962, Best Supportive Care
- Where
- 4 sites in United States, Japan
- Volunteers
- 3 people
- Sponsor
- Pfizer
Liver Cancer
A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.
This single arm study evaluated the efficacy and safety of a combination of Tarceva and Avastin in patients with advanced or metastatic liver cancer.
- Trial name
- NCT00605722
- Testing
- bevacizumab (Avastin), erlotinib (Tarceva)
- Where
- 6 sites in Philippines, South Korea and 1 more
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche
Solid Tumors, Cancer
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
This is a Phase 2 study to evaluate the efficacy and safety of cabozantinib (XL184) in subjects with selected advanced tumor types.
- Trial name
- NCT00940225
- Testing
- Cabozantinib
- Where
- 47 sites in United States, Belgium and 3 more
- Volunteers
- 730 people
- Sponsor
- Exelixis
Liver Cancer
Treatment of Primary Liver Tumors With Electrochemotherapy (ECT)
The aim of the study is to evaluate toxicity and effectiveness of electrochemotherapy with bleomycin in treatment of primary liver tumors in clinical study phase I and II.
- Trial name
- ECT-HCC (NCT02291133)
- Testing
- Electrochemotherapy, Cliniporator Vitae®, Bleomycin PHC 15 e. (United States Pharmacopeia - USP)
- Where
- Slovenia
- Volunteers
- 25 people
- Sponsor
- Masa Bosnjak
Hepatocellular Carcinoma, HCC
Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver Transplant
This study will compare stereotactic body radiation therapy (SBRT) to trans-arterial chemoembolization (TACE) as a bridging strategy for patients with HCC undergoing orthotopic liver transplantation.
- Trial name
- SBRTvsTACE (NCT02182687)
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Trans-Arterial Chemoembolization (TACE), Doxorubin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Lahey Clinic
HCC, Cancer of Liver
Low-dose Y90 Treatment Planning for HCC
The study proposes low-dose Y90 microspheres for therapy planning of HCC, as an alternative to Technetium (99mTc) albumin aggregated (MAA), to be a bioidentical therapeutic Y90 surrogate marker to better predict and thus achieve…
- Conditions
- HCC, Cancer of Liver, Cancer
- Trial name
- NCT04172714
- Testing
- SIR-Spheres microspheres
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Emory University
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
This phase II trial is studying how well MK2206 works in treating patients with advanced liver cancer that did not respond to previous therapy.
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma
- Trial name
- NCT01239355
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis
- Where
- 22 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Hepatocellular
Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
The purpose of this study is to determine the efficacy and safety of pembrolizumab or placebo given with best supportive care (BSC) in Asian participants with previously systemically treated advanced hepatocellular carcinoma…
- Trial name
- NCT03062358
- Testing
- pembrolizumab, best supportive care (BSC)
- Where
- 41 sites in China, Hong Kong and 3 more
- Volunteers
- 453 people
- Sponsor
- Merck Sharp & Dohme LLC
Liver Cancer
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
The goal of this clinical research study is to learn if the combination of AvastinTM (bevacizumab) and Tarceva (erlotinib hydrochloride) can help to control advanced liver cancer.
- Trial name
- NCT01180959
- Testing
- Bevacizumab, Erlotinib
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- M.D. Anderson Cancer Center
Biliary Carcinoma, Gall Bladder Carcinoma
Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
The purpose of this study is to see if an experimental drug, called copanlisib is effective and safe in treating adult participants with cholangiocarcinoma, when used in combination with gemcitabine and cisplatin.
- Conditions
- Biliary Carcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma, Gastrointestinal Tumor
- Trial name
- NCT02631590
- Testing
- Cisplatin, Gemcitabine, Copanlisib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Hepatocellular Carcinoma
Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215)
The purpose of this study is to characterize the baseline variability of a panel of tissue (tumor and adjacent) and blood-based biomarkers obtained from participants with hepatocellular carcinoma (HCC).
- Trial name
- NCT01521780
- Testing
- MRI, Pathology, Blood Samples
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatocellular Carcinoma
A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib
This is a Phase 3 multicenter, randomized study evaluating the safety and efficacy of ramucirumab DP plus BSC as a double-blind, placebo-controlled (placebo plus BSC) comparison.
- Trial name
- REACH (NCT01140347)
- Testing
- Ramucirumab DP (IMC-1121B), BSC
- Where
- 146 sites in United States, Australia and 25 more
- Volunteers
- 565 people
- Sponsor
- Eli Lilly and Company
Gastrointestinal Cancers, Cholangiocarcinoma
Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers
Prospective, multi-center, open label, non-randomized clinical trial to assess efficacy of [18F]FAPI-74 to detect FAP expressing cells in patients diagnosed with gastrointestinal cancers, including hepatocellular carcinoma…
- Conditions
- Gastrointestinal Cancers, Cholangiocarcinoma, Gastric Cancer, Colorectal Cancer
- Trial name
- 18F-FAPI-74 GI (NCT05641896)
- Testing
- [18F]FAPI-74 PET/CT
- Where
- 6 sites in United States
- Volunteers
- 112 people
- Sponsor
- SOFIE
Lung Cancer, Breast Cancer
Measuring and Improving the Safety of Test Result Follow-Up
Improving communication is foundational to improving patient safety. Electronic health records (EHRs) can improve communication, but also introduce unique vulnerabilities.
- Conditions
- Lung Cancer, Breast Cancer, Colon Cancer, Bladder Cancer
- Trial name
- NCT04166240
- Testing
- SAFER TRACKS Intervention
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- VA Office of Research and Development
Liver Cancer
Chemoembolization Using Doxorubicin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing.
- Trial name
- NCT00293397
- Testing
- Drug-eluting beads loaded with doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yale University
Liver Diseases, Liver Cancer
Breath Analysis Based Disease Biomarkers
The purpose of the study is to develop a clinical test based on breath analysis that can be used for disease diagnosis or prognosis.
- Conditions
- Liver Diseases, Liver Cancer, COVID19
- Trial name
- NCT04341012
- Testing
- Collection of breath sample
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Hepatocellular Carcinoma (HCC)
A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)
This is a study to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma…
- Trial name
- NCT03071094
- Testing
- Pexastimogene Devacirepvec (Pexa Vec), Nivolumab
- Where
- 2 sites in France
- Volunteers
- 14 people
- Sponsor
- Transgene
Liver Cancer, Metastatic Cancer
Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor.
- Trial name
- NCT00003907
- Testing
- cisplatin, doxorubicin, mitomycin
- Where
- 37 sites in United States
- Volunteers
- 50 people
- Sponsor
- Eastern Cooperative Oncology Group
Colorectal Cancer, Metastatic Cancer
Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer
RATIONALE: Vaccines made from a gene-modified virus and a person's white blood cells may make the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00103142
- Testing
- falimarev, inalimarev, sargramostim
- Where
- 6 sites in United States
- Volunteers
- 74 people
- Sponsor
- Michael Morse, MD